Aura Biosciences, Inc. (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 2,534 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 2,534 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total value of $19,638.50. Following the transaction, the insider now owns 269,794 shares in the company, valued at $2,090,903.50. This represents a 0.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Aura Biosciences Trading Down 3.8 %

Shares of NASDAQ:AURA traded down $0.30 during trading on Tuesday, hitting $7.65. 213,354 shares of the company’s stock were exchanged, compared to its average volume of 139,966. The firm has a 50-day moving average price of $8.07 and a two-hundred day moving average price of $8.76. The firm has a market cap of $382.12 million, a P/E ratio of -4.42 and a beta of 0.29. Aura Biosciences, Inc. has a 1-year low of $6.63 and a 1-year high of $12.38.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its stake in Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after purchasing an additional 3,612 shares during the period. Geode Capital Management LLC grew its stake in shares of Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after acquiring an additional 3,972 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Aura Biosciences by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock valued at $227,000 after purchasing an additional 5,930 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Aura Biosciences in the fourth quarter worth $50,000. Finally, Bank of America Corp DE boosted its holdings in Aura Biosciences by 20.5% during the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock worth $422,000 after purchasing an additional 8,709 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AURA. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a report on Thursday, November 14th. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.